Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison ; day:6 ; month:3 ; year:2024 ; pages:1-12
Rheumatology and therapy ; (6.3.2024), 1-12

Creator
Mease, Philip J.
Warren, Richard B.
Nash, Peter
Grouin, Jean-Marie
Lyris, Nikos
Willems, Damon
Taieb, Vanessa
Eells, Jason
McInnes, Iain B.
Contributor
SpringerLink (Online service)

DOI
10.1007/s40744-024-00652-7
URN
urn:nbn:de:101:1-2405100925200.364160063085
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:47 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Mease, Philip J.
  • Warren, Richard B.
  • Nash, Peter
  • Grouin, Jean-Marie
  • Lyris, Nikos
  • Willems, Damon
  • Taieb, Vanessa
  • Eells, Jason
  • McInnes, Iain B.
  • SpringerLink (Online service)

Other Objects (12)

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison

Secukinumab: A Review in Psoriatic Arthritis

Secukinumab: A Review in Psoriatic Arthritis

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Secukinumab: A New Treatment Option for Psoriatic Arthritis

Correction to: Secukinumab: A Review in Psoriatic Arthritis

Correction to: Secukinumab: A Review in Psoriatic Arthritis

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis

A Review of the Use of Secukinumab for Psoriatic Arthritis

A Review of the Use of Secukinumab for Psoriatic Arthritis

Two-stage matching-adjusted indirect comparison

Two-stage matching-adjusted indirect comparison

Related objects